Description: Helix BioPharma is a biopharmaceutical company specializing in the field of cancer therapy. The Company is developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's clinical product development initiatives include Topical Interferon Alpha-2b, for the treatment of conditions caused by the human papilloma virus. Helix is also developing its novel L-DOS47 new drug product candidate for the treatment of lung adenocarcinoma.
Home Page: www.helixbiopharma.com
401 Bay Street
Toronto,
ON
M5H 2Y4
Canada
Phone:
905 841 2300
Officers
| Name | Title |
|---|---|
| Mr. Hatem Kawar M.B.A., MBA, P.Eng, P.Eng. | Chief Financial Officer |
| Dr. Gabrielle M. Siegers M.A., Ph.D. | Head of R&D |
| Ms. Namrata Malhotra | Corp. Sec. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 134.7204 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | July |
| Full Time Employees: | 7 |